Once past the first thirty minutes of NP's usual a
Post# of 148177
And I liked that Dr. Recknor had the good taste to also publicly thank and credit doctors/others outside the company like Jonah Sacha, Dr. Steven Hansen ( also of OHSU Hospital & Science) and Otto Yang for their efforts and input, especially with regards to receptor occupancy.
I feel shareholders being served well by those now in charge, although still lacking in partnership/licensing deals - or government NIH/other funds for trial completion. Like everyone else, anxious to hear full progress report in mid April.